Medical insurance reimbursement policy for avatrombopag/Sucoxin

Avatrombopag/Avatrombopag is a thrombopoietin receptor agonist used for the preoperative treatment of thrombocytopenia in patients with chronic liver disease and chronic refractory thrombocytopenia. As an effective drug for the treatment of thrombocytopenia associated with chronic liver disease, its medical insurance reimbursement policy provides important financial support to patients. After the drug was launched in China, it has been included in the national Class B medical insurance reimbursement list through the relevant policies of the National Medical Insurance Administration, which means that eligible adult patients can enjoy the benefits of medical insurance reimbursement when using avatrombopag.

Specifically, the Medicare reimbursement policy targets adult patients with chronic liver disease-related thrombocytopenia who undergo elective diagnostic procedures or surgeries. This restriction ensures targeted and effective drug use while avoiding waste of resources. When patients purchase avatropopag, they need to submit detailed medical records, diagnosis certificates, and prescriptions for avatropopag treatment issued by doctors for review by the medical insurance agency.

In terms of reimbursement ratio, due to differences in regions and medical insurance policies, the specific reimbursement ratio will vary, but generally speaking, patients can enjoy a certain proportion of reimbursement, thereby reducing the financial burden. In addition, after being included in medical insurance, the price of avatrombopag has also dropped significantly, further bringing benefits to patients.

It is worth noting that when enjoying the medical insurance reimbursement policy, patients should ensure that they meet the reimbursement conditions and understand the specific reimbursement ratio and process. At the same time, in order to ensure the quality and safety of the drug, it is recommended that patients purchase avatrombopag through hospital pharmacies or regular pharmacies and avoid purchasing from informal channels.